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The aim of this study was to identify factors that may be associated with the development of bone metastases in patients with
metastatic breast carcinoma and to see if any of these factors had a bearing on subsequent survival. In total, 492 patients presented to
the Nottingham City Hospital with metastatic breast carcinoma between July 1997 and December 2001. Of these, 267 patients had
bone metastases at presentation with metastatic disease, 91 patients in this group had bone as their only site of metastatic disease.
Sites of first presentation of metastatic disease were prospectively recorded, as were histological features of the primary tumour
(tumour type, histological grade, lymph node stage, tumour size and oestrogen receptor (ER) status). The radiological features of the
bone metastases, the metastasis-free interval and serological tumour marker levels at presentation with metastases were all recorded.
There was a significant association between the development of bone metastases and lower grade tumours (P¼0.019), ER-positive
tumours (Po0.0001) and the lymph node stage of the primary tumour (P¼0.047). A multivariate analysis found that metastasis-free
interval, additional sites of metastatic disease other than bone, ER status and serological tumour marker levels all independently
contributed to survival from time of presentation with bone metastases.
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The survival of patients with metastases is variable ranging from a
matter of months to many years. The ability to predict prognosis
and response to treatment has a considerable impact on patient
management. It is well established that oestrogen receptor (ER)
status and site of presentation of metastatic disease have the
greatest impact on patient survival, with additional contributions
made by patient age, disease-free interval and histological grade.
Bone is the most common site of metastases in patients with
breast carcinoma and so patients with bone metastases make up
the largest single group of patients presenting with metastatic
disease. It has previously been reported that 20% of patients with
bone metastases survive for more than 5 years, which emphasises
the wide variation in survival seen in this group of patients
(Coleman et al, 1987). The aim of this study was to identify factors
that may be associated with the development of bone metastases
and to see if any of these factors had any bearing on subsequent
survival.
We have assessed traditional factors such as ER status,
histological grade, lymph node stage and size of the primary
tumour, patient age, metastasis-free interval and the presence of
metastases at sites other than bone. We have examined the
radiological appearance of the bone metastases and looked for
associations with the histological features of the tumour and
patient survival. In common with other centres, we increasingly
use serological tumour markers in the diagnosis and monitoring of
patients with metastatic breast carcinoma. The prognostic
significance of elevated tumour markers at presentation with bone
metastases was also studied. Prognostic features were assessed in a
univariate and multivariate fashion.
METHOD
Between July 1997 and December 2001, 492 patients presented to
our unit with newly diagnosed metastatic breast carcinoma. The
group consisted of patients presenting with metastatic disease
following a previous diagnosis of breast carcinoma and patients
with metastatic disease at the time of initial diagnosis of breast
cancer (stage 4).
Virtually all patients were initially investigated for metastatic
disease due to a clinical symptom or sign. At presentation, patients
were routinely assessed for metastatic disease in the bones, chest
and liver. In the first instance, plain radiographs were used to
assess the chest and bones. A radiograph of the pelvis was obtained
routinely, supplemented with radiographs of any symptomatic
areas. Bone metastases visible on the plain radiograph were
recorded as being sclerotic, lytic or mixed. Bone scintigraphy,
computed tomography (CT) and magnetic resonance (MR)
imaging were used when the diagnosis was uncertain or equivocal.
Bone lesions not visible on plain radiographs, but identified on the
other imaging modalities were described as occult. The presence of
liver metastases was determined using ultrasound or less
frequently CT. Sites of metastatic disease at first presentation
were prospectively recorded.
Tumour markers were recorded at the time of first presentation.
The markers routinely measured at our institution are erythrocyte
sedimentation rate (ESR), carcinoembryonic antigen (CEA) and
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ycancer antigen 15.3 (CA15.3). CEA was said to be elevated above a
value of 10ngml
 1 and CA15.3 was elevated above a level of
35Uml
 1.
Pathological data were obtained from the patients previous
mastectomy or wide local excision specimens. Histological grade,
lymph node stage, tumour size, ER status and tumour type were
recorded for each patient where possible. Tumour types included
Ductal No Specific Type (Ductal NST), Tubular Mixed, Lobular,
Mixed ductal and lobular and pure tubular; details of the
classification of tumour types are well described elsewhere (Ellis
et al, 1992). The tumour grade was assessed by the Nottingham
method (Elston et al, 1991). Lymph node stage was determined
from the results of axillary node sampling or dissection: stage 1
disease – no nodal involvement; stage 2 disease – three nodes or
less containing tumour; stage 3 disease – four or more nodes
containing tumour. For patients diagnosed with primary breast
cancer before 1995, ER activity was measured using the standard
radioligand binding assay on tissue cytosol samples; the threshold
for the designation of ER positivity being 10fmolmg
 1 of protein.
More recently ER status has been determined using immunocy-
tochemical methods, with an H-score 450 identifying ER-positive
tumours. For patients presenting with locally advanced primary
tumours, ER status was determined by core biopsy at the time of
presentation. In this situation, provisional tumour grade obtained
from core biopsy was not included. All the pathology was reported
by one of three specialist breast pathologists, using standard
pathological techniques.
Metastasis-free interval was calculated. This was defined as the
interval between first diagnosis of breast cancer and time of first
presentation with metastatic disease. Survival from diagnosis of
metastases was determined from the hospital computer system of
patient attendances and deaths, contacting the patient’s general
practioner and from the local health authorities patient records.
Throughout the study period patient management remained
consistent. Endocrine therapy was the preferred first-line method
of treatment in patients with metastatic breast carcinoma.
Exceptions to this were patients with widespread or life-threaten-
ing visceral metastases. These patients and those with ER-negative
tumours were advised to have chemotherapy, if considered fit. The
endocrine treatments of choice included the ER antagonist
Tamoxifen or an aromatase inhibitor (Anastrozole). Gonadorelin
analogues (Goserelin) were used in premenopausal women to
achieve ovarian ablation. Bisphosphonates were prescribed routi-
nely for patients with bone metastases according to a defined
protocol.
Survival curves were calculated for each factor analysed, using
the Kaplan–Meier method. A Cox multivariate analysis was used
to establish which of the factors independently contributed
towards prolonged survival after the presentation with bone
metastases. The statistical analysis was performed using StatView
5.0 for Apple Macintosh (SAS Institute Inc., Cary, NC, USA).
RESULTS
The distribution of metastatic disease in the patient group is
shown in Table 1. Bone metastases were the most frequently
observed metastases. In all, 267 (54%) patients had bone
metastases as their first site of presentation of metastatic disease.
Of these, 170 patients had no evidence of bone metastases at
presentation. Baseline bone investigations were not performed or
incomplete in 55 patients presenting with metastases at other sites.
These patients were excluded from subsequent analysis. In all, 91
patients had bone metastases as their only site of metastatic
disease at presentation.
The patient and tumour characteristics of the study population
(n¼437) are shown in Table 2. There is a significant relationship
between bone metastases as the first presentation of metastatic
disease and histological grade of the primary tumour. Bone
metastases were significantly more likely to be associated with a
lower grade primary tumour (w
2¼7.90, P¼0.019). Patients
presenting with bone metastases were significantly more likely to
have ER-positive primary tumours compared to patients who
presented with metastatic disease at other sites (w
2¼19.76,
P¼o0.0001). Bone metastases were also more likely to be
associated with lymph node-positive primary tumours (w
2¼6.13,
P¼0.047). Bone metastases were more frequently observed in
patients with Tubular Mixed primary tumours compared with
Ductal NST (w
2¼5.03, P¼0.025). No significant association with
bone metastases was observed for the other tumour types
including lobular carcinomas. Presentation with bone metastases
was not related to the patient’s age or the size of the primary
tumour.
The radiographic appearances of the bone metastases and the
tumour characteristics are shown in Table 3. There was no
relationship between whether the bone metastases were visible or
occult on plain radiographs and the histological grade of the
primary tumour (w
2¼0.10, P¼0.608) or the ER status of the
primary tumour (w
2¼0.98, P¼0.322). There was also no relation-
ship between the radiographic appearances of the bone metastases
(i.e. lytic, sclerotic or mixed) and the grade of the primary tumour
(w
2¼2.52, P¼0.641) or the ER status of the primary tumour
(w
2¼0.58, P¼0.749). There was no relationship between the
radiographic appearance of the bone metastases and the type of
primary tumour (w
2¼11.81, P¼0.461).
Seven of the factors analysed were found to contribute
significantly towards prolonged survival in patients presenting
with bone metastases. These were ER status (P¼0.0003, Figure 1),
histological grade (P¼0.034), additional sites of metastatic disease
(P¼0.0004, Figure 2), patient age (P¼0.0003), number of hot
spots on bone scan (P¼0.040) and metastasis-free interval
(P¼0.0045, Figure 3). Levels of the tumour markers CA 15.3
and CEA at presentation were also significantly related to survival
(P¼0.0026 and 0.017, respectively, Figures 4 and 5). The radio-
graphic appearance of the bone metastases, histological tumour
type, lymph node stage, primary tumour size and ESR at
presentation with bone metastases were not significantly related
to survival.
Three of the factors analysed were also found to contribute
significantly to survival in the 91 patients with bone as their only
site of metastatic disease. These were ER status (P¼0.018), Ca 15.3
(P¼0.025) and metastasis-free interval (P¼0.004). In the same
group of patients there was a trend for worsening survival if the
CEA level was elevated at presentation, but this did not reach
statistical significance.
A Cox multivariate analysis found that a long metastasis-free
interval, absence of metastases at sites other than bone, ER-
positive tumours, normal CEA and CA15.3 levels at presentation
all contributed independently towards prolonged survival from
time of presentation with bone metastases (Table 4).
Table 1 Sites of first presentation of metastatic breast carcinoma
Site of first presentation of metastases
Number of patients
(%) (n¼492)
Bone 267 (54)
Bone metastases only 91
Bone metastases and other metastases 176
Nonbony metastases only 170
Chest 186 (38)
Liver 144 (29)
Ascites 19 (4)
Brain 15 (3)
Ovarian 7 (1)
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yDISCUSSION
Prognostic factors for metastatic breast carcinoma have received
less attention than prognostic factors for primary disease. This
may in part be due to the inherent difficulty in separating whether
a factor is a ‘pure’ prognostic factor, a predictive factor for
response to therapy or both. For primary breast carcinoma there
are historical series where patients received no systemic adjuvant
therapy and later series where they did. Consequently, the
potential value of factors as prognostic or predictive can be teased
out more easily. For patients with metastatic disease, where
virtually all patients receive treatment, such distinctions are more
difficult.
Many groups have studied prognostic factors in patients
presenting with metastatic breast carcinoma. Patients with bone
metastases make up the largest single group of patients presenting
with metastatic disease. As a consequence, prognostic factors
related to this specific group of patients are worthy of more
detailed study.
Additional sites of metastatic disease at presentation with bone
metastases dramatically worsened survival, with those patients
presenting with lung and liver metastases doing significantly worse
than those patients presenting with bone metastases alone. Others
have also confirmed the importance of site of initial metastases in
determining prognosis (Blanco et al, 1990; Robertson et al, 1992;
Coleman et al, 1998; Solomayer et al, 2000).
Factors that indicate a less aggressive tumour phenotype were
associated with the development of bone metastases. Low-grade
and ER-positive tumours were more likely to be associated with
the development of bone metastases. Others have also found
similar relationships (Koenders et al, 1991; Coleman et al, 1998;
Solomayer et al, 2000). The same factors were also found to
influence survival in patients presenting with bone metastases.
Those with low-grade and ER-positive tumours showed signifi-
cantly prolonged survival compared with patients with high-grade
or ER-negative tumours. A shorter metastasis-free interval also
had a negative impact on survival in patients with bone metastases.
This confirms previous work recognising the prognostic impor-
tance of the metastasis-free interval (Solomayer et al, 2000). A
short metastasis-free interval also tends to suggest a more
aggressive, rapidly growing tumour.
The multivariate analysis showed ER status rather than
histological grade as an independent prognostic factor for survival
in patients presenting with bone metastases. The close relationship
Table 2 Correlation between presentation with bone metastases and primary tumour characteristics
Bone metastases at presentation with metastatic
disease
Tumour characteristics Yes No Univariate analysis
Histological grade (%) 1 14 (70) 6 (30) w
2¼7.90
2 71 (68) 34 (32) P¼0.0193
3 94 (52) 87 (48)
ER status (%) +VE 157 (69) 71 (31) w
2¼19.755
 VE 60 (45) 73 (55) Po0.0001
Lymph node stage (%) 1 29 (48) 31 (52) w
2¼6.13
2 70 (68) 33 (32) P¼0.0467
3 40 (60) 27 (40)
Primary tumour size (mm) (%) o15 23 (55) 19 (45) w
2¼4.389
15–30 56 (37) 96 (63) P¼0.1114
430 35 (40) 52 (60)
Patient age (%) p40 15 (56) 12 (44) w
2¼2.889
41–50 46 (64) 26 (36) P¼0.5766
51–60 56 (56) 44 (44)
61–70 59 (60) 40 (40)
470 91 (65) 48 (35)
Tumour type (%) Ductal NST 114 (56) 89 (44) Ductal NST vs tubular mixed
w
2¼5.03 P¼0.025
Tubular mixed 24 (77) 7 (23)
Lobular 25 (69) 11 (31)
Mixed ductal and lobular 10 (50) 10 (50) Ductal NST vs lobular w
2¼2.22
P¼0.136
Pure tubular 2 (67) 1 (33)
Table 3 Association between the radiographic appearance of the bone metastases and the primary tumour characteristics
Histological grade (%) ER status (%) Tumour type (%)
Radiographic appearance
of bone metastases
1 2 3 +VE  VE Ductal NST Tubular
mixed
Lobular Mixed ductal
and lobular
Pure
tubular
Occult 3 (21.5) 11 (15.5) 20 (22) 32 (21) 16 (28) 22 (20) 3 (12.5) 7 (28) 0 0
Visible
Lytic 7 (50) 27 (38.5) 38 (41) 59 (39) 18 (31) 48 (43) 9 (37.5) 10 (40) 3 (25) 2 (100)
Mixed 3 (21.5) 14 (20) 16 (17) 30 (20) 11 (19) 19 (17) 7 (29) 3 (12) 4 (33) 0
Sclerotic 1 (7) 18 (26) 18 (20) 31 (20) 13 (22) 22 (20) 5 (21) 5 (20) 5 (42) 0
Univariate analysis NS NS NS
NS¼no significant relationship.
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ybetween ER status and grade is well recognised with ER activity
occurring more frequently in well-differentiated tumours (Wil-
liams et al, 1987). The reason ER status correlates better with
survival is in large part due to the fact that ER status predicts for
response to endocrine therapy. The ER is involved in the actual
pathway inhibited by endocrine therapy, whereas histological
grade is a composite measure of three factors (tubule formation,
nuclear pleomorphism and frequency of mitoses) which are
themselves not based on a single cellular process. It is perhaps
not surprising that ER status is better than histological grade at
predicting survival.
One rather curious association was that patients with bone
metastases were more likely to have had lymph node metastases at
the time of diagnosis of their primary tumour. This may just be a
chance finding, but may also be explained by the close relationship
between ER status and histological grade. Bone metastases are
more likely to occur in ER-positive tumours. There is a strong
correlation between ER positivity and well-differentiated tumours
(Williams et al, 1987). Well-differentiated tumours are unlikely to
metastasise unless lymph node positive, unlike poorly differen-
tiated lymph node negative tumours which will still often
metastasise. This may be a possible explanation for the association
between lymph node metastases and bone metastases.
It is well established that for primary breast cancer lymph node
stage, histological grade and to a lesser extent tumour size are
powerful prognostic features. As has also been previously
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Figure 1 Survival for patients with bone metastases by ER status.
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Figure 2 Survival for patients with bone metastases only compared to
those with bone and other sites of metastatic disease.
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patient develops metastatic disease then neither the lymph node
status nor the size of the primary tumour is relevant as predictors
of survival.
It is well known that the metastatic patterns of lobular and
ductal carcinomas are different, with gastrointestinal and perito-
neal metastases being more common in lobular carcinomas (Dixon
et al, 1991). There has been debate in the literature as to whether
tumour type has any bearing on the development of bone
metastases. Tubular mixed primary tumours were more likely to
develop bone metastases compared to Ductal NST tumours. This
finding helps to support the argument that less-aggressive tumour
phenotypes are more likely to be associated with the development
of bone metastases. In common with several previous studies, we
found no evidence that patients with lobular carcinoma were more
likely to develop bone metastases compared to patients with ductal
carcinomas (Dixon et al, 1991; Fondrinier et al, 1997). Others have
suggested that lobular carcinomas have a tendency to metastasise
to bone (Borst et al, 1993; Sastre-Garau et al, 1996).
Patient age does not appear to be a factor in the development of
bone metastases, with bone metastases distributed fairly evenly
across the age ranges. Others have also confirmed the lack of an
age-related trend in the development of bone metastases (De la
Monte et al, 1988). It has previously been observed that older
women are more likely to have metastatic disease that remains
confined to bone (Coleman et al, 1998). Along with others we have
also found that survival for women with bone metastases was
significantly worse over the age of 70 years (Coleman et al, 1998).
It is difficult to know whether this reflects differences in treatment,
or the increased likelihood of dying from other conditions. We
have seen a similar trend for worsening survival in our elderly
patients with liver metastases, which seems in part explained by
differences in treatment, with only 6.4% receiving chemotherapy
compared to 56% of patients under 70 years (Wyld et al, 2002).
Death from comorbid conditions has been put forward as an
argument for the apparent poor survival in individuals over 70
years of age (Yanick et al, 2001). There may even be a link in some
patients. For example, older patients have a higher incidence of
osteoporosis, which in the presence of bone metastases may result
in an increased incidence or earlier fracture rate. Fractures of long
bones are known to carry significant mortality in the elderly.
The radiographic appearance of the bone metastases was not
related to grade, ER status or type of primary tumour, nor did it
have any bearing on patient survival. The only radiographic
feature that did impact on patient survival was the number of hot
spots on bone scan. Patients with a solitary hot spot on bone scan
had significantly improved survival compared to patients with two
or more hot spots. It has previously been reported that patients
who have bone recurrence at initially only one or two sites on bone
scan experience a survival advantage over those with more
extensive skeletal metastases (Jacobson et al, 2001). Care needs
to be taken when interpreting this finding, as a possible
explanation for the apparent better outcome may be that a solitary
hot spot on a bone scan has been incorrectly classified as
malignant. Another explanation may relate to the reason for doing
the bone scan, for instance, a patient with an asymptomatic
tumour marker rise; in such a case, the apparent improved survival
may simply be ‘lead-time’ bias.
The usefulness of blood tumour markers in the diagnosis and
monitoring of response to treatment in patients with metastatic
disease is well established (Breast Speciality Group of BASO, 1999;
Robertson et al, 1999; Cheung et al, 2000, 2001). Much less has
been written about the prognostic value of tumour markers.
Correlations between raised preoperative levels of CA15.3 and CEA
with poorer outcome have been reported (Molina et al, 1998;
Shering et al, 1998; Ebeling et al, 1999; McLaughlin et al, 2000;
Canizares et al, 2001). To our knowledge, the prognostic
significance of an elevated CA15.3 and CEA in patients presenting
with bone metastases has not been previously described. Several
authors have commented on the correlation between overall
tumour burden and CA15.3 levels (O’Hanlon et al, 1995;
Tampellini et al, 2001). It is likely that elevated tumour markers
reflect tumour burden in patients presenting with bone metastases.
Analysis of the subgroup with bone as their only site of metastatic
disease revealed that patients with ER-negative tumour, elevated CA
15.3 level at presentation and a short metastasis-free interval
experienced significantly reduced survival. This may have impor-
tant implications for treatment, as patients with bone-only disease
are traditionally treated with endocrine therapies alone. Patients
with bone-only metastatic disease with ER-negative tumours,
elevated CA15.3 levels at presentation and a short metastasis-free
interval may benefit from more aggressive treatments, possibly with
chemotherapy being considered as a first-line agent.
Prognostic factors are important for patient counselling and
advising treatment options. This study has revealed several
potential independent prognostic factors in patients presenting
with bone metastases. These are ER status, metastasis-free interval,
additional sites of metastases other than bone and elevated tumour
marker levels. The factors that suggest a more aggressive tumour
phenotype, such as negative ER status and short metastasis-free
interval, are associated with a poorer outcome. Factors that are
associated with a greater tumour burden also predict for reduced
survival, these are raised tumour markers and the presence of
extraosseus disease. Factors that suggest hormone sensitivity (a
positive ER status) predict for longer survival. Awareness of the
prognostic implications of these factors may aid the selection of
the most appropriate treatment options in patients presenting with
bone metastases.
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Figure 5 Survival for patients with bone metastases by CEA level
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Table 4 Cox multivariate analysis
Factor analysed P-value Coefficient
Presentation Ca 15.3 0.0105 0.0003
Metastasis-free interval 0.0411 0.127
ER status 0.0399 0.732
Presentation CEA 0.0055 0.0004
Presence of metastases at sites other than bone 0.0314 0.780
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